Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis (Q35149729)

6 August 2017

0 references

1 reference

title

Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis (English)

1 reference

6 August 2017

1 reference

Donald A Berry

1

1 reference

6 August 2017

Scott M Berry

series ordinal

2

1 reference

6 August 2017

John McKellar

series ordinal

3

1 reference

6 August 2017

Thomas A Pearson

series ordinal

4

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

6 August 2017

American Heart Journal

1 reference

6 August 2017

145

1 reference

6 August 2017

6

1 reference

6 August 2017

1036-1045

1 reference

Current perspectives on statins

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Drug treatment of lipid disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Toward evidence-based medical statistics. 1: The P value fallacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Toward evidence-based medical statistics. 2: The Bayes factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Atorvastatin, a New HMG-CoA Reductase Inhibitor as Monotherapy and Combined With Colestipol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Understanding and testing for heterogeneity across 2 x 2 tables: application to meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Grouped random effects models for Bayesian meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Hierarchical models for multicentre binary response studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Stopping a clinical trial early: frequentist and Bayesian approaches applied to a CALGB trial in non-small-cell lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Prediction and decision making using Bayesian hierarchical models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Benefits and risks of screening mammography for women in their forties: a statistical appraisal.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Bayesian meta-analysis, with application to studies of ETS and lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Placing trials in context using Bayesian analysis. GUSTO revisited by Reverend Bayes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900106-6

10.1016/S0002-8703(03)00106-6

7 January 2021

Identifiers

DOI

1 reference

6 August 2017

1 reference